These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34558669)

  • 1. Novel Pharmacological Targets for Pulmonary Arterial Hypertension.
    Klinger JR
    Compr Physiol; 2021 Sep; 11(4):2297-2349. PubMed ID: 34558669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension: Recent Advances.
    Mercurio V; Cuomo A; Naranjo M; Hassoun PM
    Compr Physiol; 2021 Apr; 11(2):1805-1829. PubMed ID: 33792903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promising therapeutic approaches in pulmonary arterial hypertension.
    Ali MK; Ichimura K; Spiekerkoetter E
    Curr Opin Pharmacol; 2021 Aug; 59():127-139. PubMed ID: 34217109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Treatment Pathways in Pulmonary Arterial Hypertension.
    Qaiser KN; Tonelli AR
    Methodist Debakey Cardiovasc J; 2021; 17(2):106-114. PubMed ID: 34326930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Novel concepts in the pathobiology of pulmonary arterial hypertension].
    Rosenkranz S
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S167-9. PubMed ID: 18814087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension.
    Ho L; Hossen N; Nguyen T; Vo A; Ahsan F
    Biomedicines; 2022 Jan; 10(1):. PubMed ID: 35052850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension.
    Berghausen E; ten Freyhaus H; Rosenkranz S
    Handb Exp Pharmacol; 2013; 218():381-408. PubMed ID: 24092349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating epigenetics and metabolomics to advance treatments for pulmonary arterial hypertension.
    Ranasinghe ADCU; Schwarz MA
    Biochem Pharmacol; 2022 Oct; 204():115245. PubMed ID: 36096239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation in Pulmonary Arterial Hypertension.
    Klouda T; Yuan K
    Adv Exp Med Biol; 2021; 1303():351-372. PubMed ID: 33788202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension.
    Auth R; Klinger JR
    Expert Opin Investig Drugs; 2023; 32(11):1025-1042. PubMed ID: 37881882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of regenerative cell therapy for pulmonary arterial hypertension in animal models: a preclinical systematic review protocol.
    Suen CM; Zhai A; Lalu MM; Welsh C; Levac BM; Fergusson D; McIntyre L; Stewart DJ
    Syst Rev; 2016 May; 5():89. PubMed ID: 27225668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for the Treatment of Pulmonary Arterial Hypertension.
    Vazquez ZGS; Klinger JR
    Lung; 2020 Aug; 198(4):581-596. PubMed ID: 32671468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension.
    Condon DF; Agarwal S; Chakraborty A; Auer N; Vazquez R; Patel H; Zamanian RT; de Jesus Perez VA
    Chest; 2022 Apr; 161(4):1060-1072. PubMed ID: 34655569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic Targets for Oligonucleotide Therapies of Pulmonary Arterial Hypertension.
    Gerthoffer W
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Light at the ENDothelium-role of Sox17 and Runx1 in endothelial dysfunction and pulmonary arterial hypertension.
    Simmons Beck R; Liang OD; Klinger JR
    Front Cardiovasc Med; 2023; 10():1274033. PubMed ID: 38028440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery.
    Vaidya B; Gupta V
    J Control Release; 2015 Aug; 211():118-33. PubMed ID: 26036906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2α.
    Dai Z; Li M; Wharton J; Zhu MM; Zhao YY
    Circulation; 2016 Jun; 133(24):2447-58. PubMed ID: 27143681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1 signaling pathway.
    Liu P; Gu Y; Luo J; Ye P; Zheng Y; Yu W; Chen S
    Exp Cell Res; 2019 Jul; 380(1):36-46. PubMed ID: 30802452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis.
    Aldred MA; Morrell NW; Guignabert C
    Circ Res; 2022 Apr; 130(9):1365-1381. PubMed ID: 35482831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature.
    Launay D; Hachulla E; Hatron PY; Jais X; Simonneau G; Humbert M
    Medicine (Baltimore); 2007 Sep; 86(5):299-315. PubMed ID: 17873760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.